10,684 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Algert Global LLC

Algert Global LLC bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 2nd quarter, Holdings Channel reports. The fund bought 10,684 shares of the biopharmaceutical company’s stock, valued at approximately $165,000.

Several other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares during the period. CWM LLC increased its holdings in shares of Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $70,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $153,000. Finally, Headlands Technologies LLC bought a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth about $154,000. Institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 201,058 shares of company stock worth $4,018,188 over the last ninety days. Corporate insiders own 11.00% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on CPRX shares. Citigroup boosted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. HC Wainwright upped their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Truist Financial upped their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $29.50.

Catalyst Pharmaceuticals Stock Down 0.3 %

NASDAQ:CPRX opened at $19.91 on Friday. The firm has a market cap of $2.35 billion, a PE ratio of 36.87, a price-to-earnings-growth ratio of 3.27 and a beta of 0.76. Catalyst Pharmaceuticals, Inc. has a 12 month low of $11.89 and a 12 month high of $21.67. The company’s 50-day moving average price is $19.70 and its two-hundred day moving average price is $17.17.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. The firm had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. On average, research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current fiscal year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.